Furthermore, we focused on the potential impact of a Next Generation Sequencing (NGS)-based multi-gene panel of 27 genes, including BRCA1/2 genes, with the aim to understand whether expanding the analysis to a larger panel of genes may result in a percentage of healthy subjects with cancer-predisposing gene variants higher than that reported in previous studies [13,14,15]. This evidence concerns the gene BRCA1 and cancer.